The differences in numbers may be influenced from different presentation in cell percentages (% of CD45− cells vs. % of CD34+CD45− cells), variation in sample sizes (n = 22 vs. n = 6), and donor-dependent variability, despite the same sample sources from breast cancer patients and similar surface markers used for characterization. This evidence concerns the gene CD34 and breast carcinoma.